恒瑞医药与复星医药2025年上半年业绩剖析：创新驱动增长_老虎社区_美港股上老虎

恒瑞医药与复星医药2025年上半年业绩剖析：创新驱动增长

动脉网2025-08-27

2025年上半年，恒瑞医药与复星医药均实现显著业绩增长。恒瑞医药营业收入达157.61亿元，同比增长15.88%，归母净利润44.50亿元，同比增长29.67%。创新药业务是其主要增长动力，创新药销售及许可收入高达95.61亿元，占总营收的60.66%。此外，恒瑞医药在创新药出海方面取得重要进展，收到Merck Sharp & Dohme和IDEAYA的对外许可首付款共计2.75亿美元。上半年研发...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2562918607?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-27 10:42","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2562918607","market":"hk","top_or_hot":-1,"title":"恒瑞医药与复星医药2025年上半年业绩剖析：创新驱动增长","media":"动脉网","content":"<div>\n<p>2025年上半年，恒瑞医药与复星医药均实现显著业绩增长。恒瑞医药营业收入达157.61亿元，同比增长15.88%，归母净利润44.50亿元，同比增长29.67%。创新药业务是其主要增长动力，创新药销售及许可收入高达95.61亿元，占总营收的60.66%。此外，恒瑞医药在创新药出海方面取得重要进展，收到Merck Sharp & Dohme和IDEAYA的对外许可首付款共计2.75亿美元。上半年研发...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508271058189763c124&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药与复星医药2025年上半年业绩剖析：创新驱动增长</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药与复星医药2025年上半年业绩剖析：创新驱动增长\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-27 10:42 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508271058189763c124&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2025年上半年，恒瑞医药与复星医药均实现显著业绩增长。恒瑞医药营业收入达157.61亿元，同比增长15.88%，归母净利润44.50亿元，同比增长29.67%。创新药业务是其主要增长动力，创新药销售及许可收入高达95.61亿元，占总营收的60.66%。此外，恒瑞医药在创新药出海方面取得重要进展，收到Merck Sharp & Dohme和IDEAYA的对外许可首付款共计2.75亿美元。上半年研发...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508271058189763c124&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508271058189763c124&s=b","article_id":"2562918607","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508271058189763c124&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2562918607","pubTimestamp":1756262520,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2025年上半年，恒瑞医药与复星医药均实现显著业绩增长。创新药业务是其主要增长动力，创新药销售及许可收入高达95.61亿元，占总营收的60.66%。此外，恒瑞医药在创新药出海方面取得重要进展，收到Merck Sharp & Dohme和IDEAYA的对外许可首付款共计2.75亿美元。上半年研发投入38.71亿元，占营业收入的24.56%，多个创新药获批上市或进入临床试验阶段。复星医药上半年实现营收195.14亿元，归母净利润17.02亿元，同比增长38.96%。创新药品收入超过43亿元，同比增长14.26%。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01276":"恒瑞医药","LU0359201612.USD":"贝莱德中国基金A2","02196":"复星医药","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","BK1593":"医美概念股","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","BK1191":"制药","BK1515":"抗疫概念","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC"},"translate_title":"Analysis of Hengrui Medicine and Fosun Pharma's performance in the first half of 2025: Innovation drives growth","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1,"02196":1},"content_text":"2025年上半年，恒瑞医药与复星医药均实现显著业绩增长。恒瑞医药营业收入达157.61亿元，同比增长15.88%，归母净利润44.50亿元，同比增长29.67%。创新药业务是其主要增长动力，创新药销售及许可收入高达95.61亿元，占总营收的60.66%。此外，恒瑞医药在创新药出海方面取得重要进展，收到Merck Sharp & Dohme和IDEAYA的对外许可首付款共计2.75亿美元。上半年研发投入38.71亿元，占营业收入的24.56%，多个创新药获批上市或进入临床试验阶段。复星医药上半年实现营收195.14亿元，归母净利润17.02亿元，同比增长38.96%。创新药品收入超过43亿元，同比增长14.26%。复星医药在创新药研发与获批方面也取得显著进展，自主研发及许可引进的多个创新药品和仿制药品种获批或申报上市。斯鲁利单抗注射液在欧盟、英国、印度等地获批用于广泛期小细胞肺癌的一线治疗，创新型小分子CDK4/6抑制剂复妥宁也已获批。两家公司在创新药领域的持续投入和市场拓展为行业发展注入了活力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}